Venn Life Sciences Share Discussion Threads

[rivaldo] 07/6/2016 14:04

Good news - thx bb2:

"Tried and tested: Initiating with an 'Outperform' rating

June 7 2016
DAVY VIEW

Venn Life Sciences is a small-cap clinical research organisation (CRO) building scale in an attractive segment of healthcare outsourcing. Now that it is profitable and cash-generative, the business has the potential to grow rapidly, internally and externally. Venn’s valuation – it is on a forward-year P/E of 14.3x and EV/EBITDA of 8.1x – leaves plenty of scope for it to outperform."

Hybridan forecast 2.12p EPS this year, so presumably Davy's "forward-year" P/E is actually current year, just different terminology.

[battlebus2] 07/6/2016 08:17

Davy initiates with outperform recommendation...

[cumnor] 05/6/2016 21:53

Perhaps they might consider Venn as a potential earner to replace the above?

[cocker] 31/5/2016 08:08

I can only second guess a good write up in Techinvest is why we are seeing a rise this morning.

[playful] 26/5/2016 19:46

Welcome aboard, I've been here since 2014 and never had any regrets.

[chadders] 25/5/2016 14:55

Just bought into this and have high hopes for the future - it's a keeper for me. Very encouraging finals and seems to be catching the eye.

[rivaldo] 20/5/2016 13:55

Amati Global have just emailed out their quarterly newsletter, and VENN get great exposure as one of three featured stocks as follows:



"Venn Life Sciences is a clinical research organisation providing drug development, clinical trial management and resourcing to pharmaceutical, biotechnology and medical device clients.

Venn has adopted a ‘buy and build’ strategy to consolidate a fragmented European
market and now has operations in Ireland, Germany and France. In targeting acquisitions, Venn looks to fill in the gaps in its portfolio of service offerings as well as adding to its geographic coverage. This has obvious
attractions to its clients, who tend to operate globally and prefer to deal with one service provider rather than multiple supplier in multiple territories.

Venn has been around for 25 years and has built a good reputation within its market, having completed over 300 clinical trials. It is this experience and high standard of customer service that the business relies upon. Now over 70% of
contracts come each year from repeat customers.

From an investor’s point of view, this provides good revenue visibility - the
order backlog (contracted work) and the pipeline tend to be healthy at the beginning of each financial year, de-risking the market forecasts.

Recent contract awards include a €3m contract with a European biotech for an orphan disease; a €2.4m trial for a new stent for a European medical device customer; and a phase IV allergic disease drug trials contract from a global pharmaceutical company. Venn is now held in both Amati VCT plc and Amati VCT 2 plc."

[interceptor2] 19/5/2016 10:00

Appreciate you both posting the broker estimates, checked with TDW and they are highlighting the Hybridan ones, but both sets of forecasts indicate that VENN are good value at this level.

It will be interesting to see what plans they have for Innovenn.

[penpont] 17/5/2016 21:46

Post deleted

[thomasthetank1] 12/5/2016 14:04

Read Hybridan's note on VENN LIFE SCIENCES HOLDINGS (VENN), out this morning, by visiting hxxps://www.research-tree.com/company/GB00B9275X97

"The growing European Contract Research Organisation (CRO) has reported final results for the year to December 2015. Revenue growth of 135% to €11.47m exceeded our already upgraded revenue forecast of €11.2m. Underlying Group EBITDA showed a €1.9m swing from a €1.53m loss to a profit of €0.39m vs our forecast of €0.49m. We attribute this shortfall to development costs at Innovenn. EBITDA attributable to the CRO business was €0.8m. Depreciation and amortisation charges were €0.46m vs our expectation of €0.22m. The company..."

[rivaldo] 11/5/2016 06:51

Nice summary of the results, with this brief comment from Hybridan...

http ://www.proactiveinvestors.co.uk/companies/news/125738/venn-life-hails-breakthrough-year-125738.html

Extract:

"House broker Hybridan said the revenue growth exceeded its already upgraded revenue forecast of €11.2mln"

It seems pretty clear that Innovenn is to be spun off separately:

"Having made progress on the Labskin and Clarogel initiatives, both of which are now through the development phase and into commercialisation, the board intends to reposition the Innovenn business to put it on an independent footing, so it can source its own funding and be valued as a discrete entity.

The board is actively looking at ways to realise shareholder value in 2016 for the Labskin (living skin) and Clarogel (anti-acne compound) technologies.

“The board intends implementing this repositioning in a manner that has a clear quantifiable benefit for Venn shareholders, and gives greater visibility to the strongly performing core CRO business," said Tony Richardson, chairman and chief executive officer of Venn."

[cocker] 10/5/2016 22:34

Not really. Accounts fully audited & trading update given just after year end. Accompanied with todays excellent results came news on Q1 which again was excellent. What more could one want?

[darlocst] 10/5/2016 22:11

Dec 31st year end and results released in May. Poor.

[mysteronz] 10/5/2016 20:24

Extrapolating the 2nd halfs results next year could look very interesting. The skin investment is also hiding a very profitable business, hopefully this can generate its own revenue.

What PE do people have us on currently

[rivaldo] 10/5/2016 09:37

Volumes are absolutely tiny, with just £32k traded today (including ISDX), so today's fall can simply be put down to a few profit-takers on results after the recent rise - indeed, there's been some buying at 28p/28.2p.

Innovenn is in the share price for free, or at least not very much, so it'll be interesting to see how VENN take this forward.

Last year's AGM statement was on 30th June, so this year's isn't far away, and given the very strong start in Q1 the statement should be a cracker.

[mulligut] 10/5/2016 09:31

Management achieving rock solid results as expected. Size matters in this type of business and while the margins are small per headcount the greater the contracts and personnel available across the spectrum of expertise the higher the capability for cross selling. This will reduce the management cost to income revenue ratio. With new contract wins this is pointing towards an increasing EBITDA for 2016.

This is a mini Warren Buffet company, so not worried about profit taking in the short term. With contracts in multi-year format there is extremely low risk of overnight negative events which is reassuring compared to the majority of other high growth shares on AIM. So tax benefit plus security. A no brainer as far as I am concerned and will continue to average in on my monthly pension program.

[paleje] 10/5/2016 09:17

Exactly, IC2, just what caught my attention. The market will eventually.

[cumnor] 10/5/2016 09:15

They are predictably chancing their arm and fishing for cheap stock from naive PIs-can't imagine many serious holders wanting out at this exciting stage, esp after revenue more than doubling-could continue at this early stage-and the hint that Innovenn could be sold or spun off as plc. imo

[ali47fish] 10/5/2016 09:14

is the fall because some people ata taking profits? 7pc is high s a fall?

[interceptor2] 10/5/2016 09:05

Pleased with these results which confirms the progress that excited investors in the last trading update.

Worth copying the following part of today's statement with reference to the board's view towards Innovenn, Obviously we can't be certain how the company will realise shareholder value, might want to sell the division or spin it off with some of the proceeds going back to shareholders imv. And then concentrate on the profitable core business?

"Innovenn has also delivered a strong year with progress on Labskin and Clarogel. Both technologies are now through their development phase and into commercialisation and the board intends to reposition this business such that it has an independent footing, its own source of funding and a value that can be clearly established. The board is actively looking at ways to realise shareholder value for these technologies in 2016."